Tekla Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Tekla Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$1.13M	Buy	+40,156	New	+$963K	0.04%	128

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Tekla Capital Management's ZNTL Position: Q2 2023 in Review

Tekla Capital Management opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2023: 40,156 shares worth $1.13M. The stake represents 0.04% of the portfolio and ranks #128 among its holdings.

134 funds tracked by Wall St. Rank hold ZNTL as of Q2 2023.

Tekla Capital Management held 40,156 shares of Zentalis Pharmaceuticals worth $1.13M as of Q2 2023.
Zentalis Pharmaceuticals was a new Tekla Capital Management position in Q2 2023.
Zentalis Pharmaceuticals made up 0.04% of Tekla Capital Management's portfolio in Q2 2023, its #128 holding.
134 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.